Why 2011 Could Be a Big Year for Pharmaceutical M&A
Just a couple of weeks after Gilead Sciences announced that it would be raising the prices of its leading HIV drugs, the company issued first quarter earnings numbers that were significantly below analyst expectations.
Join the discussion below, or Read more at Seeking Alpha.
#1 Apr 24, 2011
Good the bastards cause as much harm as good with their poison product. I hope they go bankrupt.
Add your comments below
|After Trump rally, equity investors move into h...||Mar '17||Retribution||6|
|Federal Judge Orders State Provide Mumia Abu-Ja...||Jan '17||truth hurts||1|
|Fight over $1,100 hepatitis C pills awaits next... (Dec '14)||Dec '14||reneir880||1|
|Gilead Sciences Under Investigation for Over-Ch... (Jul '14)||Jul '14||Chris||1|
|FDA Panel OKs Truvada for HIV Prevention (May '12)||May '14||Sheldon||6|
|$1,000 hepatitis C pill a tough miracle to swallow (May '14)||May '14||Hep C Veterans||1|
|Divide over HIV prevention drug Truvada persists (Apr '14)||Apr '14||juls||2|
Find what you want!
Search Gilead Sciences Forum Now
Copyright © 2017 Topix LLC